Matrix Protein 1 (M1 or M) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Matrix Protein 1 (M1 or M) – Pipeline Review, H2 2016’, provides in depth analysis on Matrix Protein 1 (M1 or M) targeted pipeline therapeutics.

The report provides comprehensive information on the Matrix Protein 1 (M1 or M), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Matrix Protein 1 (M1 or M) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for Matrix Protein 1 (M1 or M)

The report reviews Matrix Protein 1 (M1 or M) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Matrix Protein 1 (M1 or M) targeted therapeutics and enlists all their major and minor projects

The report assesses Matrix Protein 1 (M1 or M) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Matrix Protein 1 (M1 or M) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Matrix Protein 1 (M1 or M)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Matrix Protein 1 (M1 or M) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Novavax, Inc.

Redbiotec AG

Sarepta Therapeutics, Inc.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Matrix Protein 1 (M1 or M) Overview 6

Therapeutics Development 7

Matrix Protein 1 (M1 or M) - Products under Development by Stage of Development 7

Matrix Protein 1 (M1 or M) - Products under Development by Therapy Area 8

Matrix Protein 1 (M1 or M) - Products under Development by Indication 9

Matrix Protein 1 (M1 or M) - Pipeline Products Glance 10

Late Stage Products 10

Early Stage Products 11

Unknown Stage Products 12

Matrix Protein 1 (M1 or M) - Products under Development by Companies 13

Matrix Protein 1 (M1 or M) - Products under Development by Universities/Institutes 15

Matrix Protein 1 (M1 or M) - Therapeutics Assessment 17

Assessment by Monotherapy/Combination Products 17

Assessment by Mechanism of Action 18

Assessment by Route of Administration 19

Assessment by Molecule Type 21

Matrix Protein 1 (M1 or M) - Companies Involved in Therapeutics Development 23

Novavax, Inc. 23

Redbiotec AG 24

Sarepta Therapeutics, Inc. 25

Matrix Protein 1 (M1 or M) - Drug Profiles 26

(influenza (virus like particle) + respiratory syncytial virus) vaccine - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

influenza (virus like particle) vaccine - Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

influenza (virus like particle, tetravalent) vaccine - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

influenza [serotype A] vaccine - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

influenza [strain A/H7N9] (virus like particle, monovalent) vaccine - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

radavirsen - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

SARS (virus like particle) vaccine - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

Matrix Protein 1 (M1 or M) - Featured News & Press Releases 36

Jul 30, 2015: Novavax Announces Positive Data From Phase 2 Trial of Quadrivalent Seasonal Influenza VLP 36

Nov 17, 2014: Novavax Initiates Phase 2 Clinical Trial of Quadrivalent Seasonal Influenza VLP 36

Oct 29, 2014: U.S. FDA Grants Fast Track Designation to Novavax' H7N9 Influenza Virus-Like Particle Vaccine Candidate Adjuvanted With Matrix-M 37

Sep 30, 2014: Sarepta Therapeutics Announces Favorable Safety Results from Phase I Clinical Study of Influenza Drug Candidate 38

Sep 23, 2014: Novavax H7N9 Avian Influenza VLP Vaccine Candidate With Matrix-M Delivers Positive Phase 1/2 Clinical Data 38

Mar 10, 2014: Novavax Reports Initiation of Phase 1/2 Clinical Trial of Its H7N9 Avian Influenza VLP Vaccine Candidate With Matrix-M 39

Jul 29, 2013: Novavax Initiates First Phase 1 Clinical Trial of its A Influenza Vaccine Candidate 39

Jul 08, 2013: GenScript's Rush Gene Services Help Novavax Expedite 28-day Development of H7N9 Vaccine 40

Jul 08, 2013: Novavax Initiates First Phase 1 Clinical Trial of Its A(H7N9) Influenza Vaccine Candidate 40

May 10, 2013: Novavax's H7N9 VLP Influenza Vaccine Enters Animal Testing 41

Feb 27, 2013: Novavax Announces Extension of Contract for Advanced Development of Recombinant Influenza Products and Pandemic Preparedness With HHS-BARDA 41

Dec 21, 2012: Sarepta Therapeutics Enters Into Clinical Trial Agreement With NIH For Further Development Of Influenza Drug AVI-7100 42

Sep 10, 2012: Novavax Delays Testing On New Experimental Flu Vaccine 43

Jul 24, 2012: NOVAVAX Provides Update on Influenza Programs 44

Mar 30, 2012: AVI BioPharma To Present Preclinical Data From Influenza Study At 22nd European Congress Of Clinical Microbiology And Infectious Diseases 45

Appendix 46

Methodology 46

Coverage 46

Secondary Research 46

Primary Research 46

Expert Panel Validation 46

Contact Us 46

Disclaimer 47

List of Tables

List of Tables

Number of Products under Development for, H2 2016 7

Number of Products under Development by Therapy Area, H2 2016 8

Number of Products under Development by Indication, H2 2016 9

Comparative Analysis by Late Stage Development, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 11

Comparative Analysis by Unknown Stage Development, H2 2016 12

Number of Products under Development by Companies, H2 2016 13

Products under Development by Companies, H2 2016 14

Number of Products under Investigation by Universities/Institutes, H2 2016 15

Products under Investigation by Universities/Institutes, H2 2016 16

Assessment by Monotherapy/Combination Products, H2 2016 17

Number of Products by Stage and Mechanism of Action, H2 2016 18

Number of Products by Stage and Route of Administration, H2 2016 20

Number of Products by Stage and Molecule Type, H2 2016 22

Pipeline by Novavax, Inc., H2 2016 23

Pipeline by Redbiotec AG, H2 2016 24

Pipeline by Sarepta Therapeutics, Inc., H2 2016 25

List of Figures

List of Figures

Number of Products under Development for, H2 2016 7

Number of Products under Development by Indication, H2 2016 9

Comparative Analysis by Early Stage Products, H2 2016 11

Assessment by Monotherapy/Combination Products, H2 2016 17

Number of Products by Routes of Administration, H2 2016 19

Number of Products by Stage and Routes of Administration, H2 2016 19

Number of Products by Molecule Types, H2 2016 21

Number of Products by Stage and Molecule Type, H2 2016 21

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports